Report of Foreign Issuer Pursuant to Rule 13a-16 or 15d-16 (6-k)
November 17 2021 - 4:02PM
Edgar (US Regulatory)
UNITED
STATES
SECURITIES
AND EXCHANGE COMMISSION
Washington,
D.C. 20549
FORM
6-K
REPORT
OF FOREIGN PRIVATE ISSUER
PURSUANT
TO RULE 13a-16 OR 15d-16
UNDER
THE SECURITIES EXCHANGE ACT OF 1934
For the month of November 2021
Commission
File Number: 001-38764
Aptorum
Group Limited
17
Hanover Square, London, W1S 1BN
United
Kingdom
(Address
of principal executive office)
Indicate
by check mark whether the registrant files or will file annual reports under cover of Form 20-F or Form 40-F:
Form
20-F ☒ Form 40-F ☐
Indicate
by check mark if the registrant is submitting the Form 6-K in paper as permitted by Regulation S-T Rule 101(b)(1): ☐
Indicate
by check mark if the registrant is submitting the Form 6-K in paper as permitted by Regulation S-T Rule 101(b)(7): ☐
Amended
Share Option Plan
Aptorum
Group Limited (“Aptorum” or the “Company”) adopted the amended 2017 Share Option Plan (the “Amended
Share Option Plan”), as approved and authorized by the board of directors of the Company, effective November 5, 2021.
The
Amended Share Option Plan includes a share award scheme and there is no change to the maximum number of shares reserved for issue, which
amends and restates the previously adopted Share Option Plan dated October 13, 2017 (the “Original Plan”) of the Company
in its entirety and assumes all awards granted under the Original Plan.
Related Party Loan
Agreement with Talem Medical Group Limited
On November 17, 2021, Aptorum Therapeutics Limited
(the “Lender”), a wholly-owned subsidiary of the Company, entered into a loan agreement (the “Loan Agreement”)
with Talem Medical Group Limited (“Talem” or the “Borrower”). According to the Loan Agreement, the
Lender will grant a loan of up to AUD4,700,000 for the Borrower for general working capital purposes of the Borrower and its subsidiaries.
The loan is interest-bearing and secured by the entire issued shares of Talem Medical Group (Australia) Pty Limited held by the Borrower.
We consider this loan to be a related party transaction as certain insiders, including Ian Huen, our Chief Executive Officer, Executive
Director and Director of the Lender; Dr. Clark Cheng, our Chief Medical Officer, Executive Director and Director of the Lender; Darren
Lui, our President, Executive Director and Director of the Lender; Professor Justin Wu, our Independent Non-Executive Director; and Dr.
Thomas Lee, our Head of Research and Development and Director of the Lender have direct and indirect minority interests in the Borrower.
The Loan Agreement was reviewed and approved by the Company’s audit committee prior to being submitted to the Company’s full
Board of Directors for approval.
SIGNATURES
Pursuant
to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by
the undersigned, thereunto duly authorized.
Date: November 17, 2021
|
Aptorum
Group Limited
|
|
|
|
|
By:
|
/s/Sabrina Khan
|
|
|
Sabrina
Khan
|
|
|
Chief
Financial Officer
|
EXHIBIT
INDEX
3
Aptorum (NASDAQ:APM)
Historical Stock Chart
From Mar 2024 to Apr 2024
Aptorum (NASDAQ:APM)
Historical Stock Chart
From Apr 2023 to Apr 2024